Joaquim Bosch‐Barrera

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis

Neibla Priego, Lucía Zhu, Cátia Monteiro et al. · Nature Medicine · 2018 · 452 citations · Full text

Medicine, Neurobiology, Neuroscience +14

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Mariano Provencio, Ernest Nadal, J.L. González-Larriba et al. · New England Journal of Medicine · 2023 · 450 citations · Full text

Medicine, Oncology, Surgery +17

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity

Sara Verdura, Elisabet Cuyàs, Èric Cortada et al. · Aging · 2020 · 142 citations · Full text

Life Sciences, Biochemistry, Pharmacology +17

Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts

Sílvia Cufí, Bruna Corominas-Faja, Alejandro Vázquez‐Martín et al. · Oncotarget · 2012 · 137 citations · Full text

Medicine, Oncology, Pharmacology +17